A single and repeated dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of RBD7022 in subjects with normal or elevated LDL cholesterol
“A randomized, single-blind, placebo-controlled, single-center, single-dose-escalation, and multi-dose-escalation phase I trial evaluated the safety, tolerability, pharmacokinetic, and preliminary pharmacodynamic characteristics of subcutaneous RBD7022 in subjects with normal or elevated LDL cholesterol” is ongoing.
